🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — need advice Page 4

SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — need advice

GenomicsKate Sat, Jan 3, 2026 at 11:59 AM 29 replies 1,587 viewsPage 4 of 6
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Jan 3, 2026 at 5:39 PM#16

Congrats KevinCompounds!! You should be so proud of yourself. 🎉

22 16anna.melb_AU, mark_tokyo, hans_munich and 19 others
Reply Quote Save Share Report
jennifer_SEA
Member
234
890
Nov 2024
Seattle, WA
Jan 3, 2026 at 5:56 PM#17

Just wanted to say — for anyone reading this SURPASS-CVOT thread who is feeling discouraged: it gets better. The first 6 weeks are the hardest. Hang in there. 💪

13 11Dr.ReproEndo, lucas_SP_BR, lisa_labSD and 10 others
Reply Quote Save Share Report
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Jan 3, 2026 at 6:13 PM#18

+1. This mirrors my journey exactly. The SURPASS-CVOT discussion here is so valuable.

Last edited: Jan 3, 2026 at 9:13 PM
20 23NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 17 others
Reply Quote Save Share Report
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Jan 3, 2026 at 6:30 PM#19

Just wanted to say — for anyone reading this SURPASS-CVOT thread who is feeling discouraged: it gets better. The first few weeks are the hardest. Hang in there. 💪

Last edited: Jan 4, 2026 at 12:30 AM
7 1lori_vegas, Dr.PulmRoch, maya_sedona and 4 others
Reply Quote Save Share Report
carlos_SATX
Member
245
1,123
Oct 2024
San Antonio, TX
Jan 3, 2026 at 6:47 PM#20

Subscribing to this thread. SURPASS-CVOT tirzepatide is exactly what I've been researching. 🙏

3 8tommy_boulder, hyun_seoul, jim_asheville
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register